ATA ACTION OPPOSES OHIO HB 324, WARNS IN-PERSON EXAM REQUIREMENT WOULD DISRUPT OPIOID USE DISORDER CARE VIA TELEHEALTH FOR THOUSANDS OF PATIENTS


Legislation would effectively bar telehealth prescribing of Opioid Use Disorder medication and other drugs with an FDA REMS, creating a “care cliff” for Ohioans in treatment

WASHINGTON, DC, NOVEMBER 20, 2026 – ATA Action: Advocacy Shaping Virtual Care, the advocacy-focused affiliate of the American Telemedicine Association (ATA), continues its opposition to Ohio House Bill 324, which is headed to Ohio Governor Mike DeWine’s desk. The bill includes an in-person examination requirement before certain drugs can be prescribed. ATA Action warns that the provision would sharply restrict access to opioid use disorder (OUD) treatment via telehealth for thousands of Ohioans.

Several widely prescribed OUD medications, including Suboxone and other buprenorphine-containing products, are subject to a U.S. Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS). Under HB 324, providers would be unable to prescribe these medications via telehealth without a prior in-person exam. This would block new patients from starting care via telehealth, significantly limiting access to care, and disrupting treatment for patients who currently rely on virtual care.

“Ohioans in recovery should not lose access to life-saving treatment because of an arbitrary, one-size-fits-all mandate,” said Hunter Young, Head of State Government Relations for ATA Action. “Telehealth providers are held to the same standard of care as in-person providers, and when an in-person exam is clinically necessary, it is the provider’s responsibility to ensure the patient gets one. That decision belongs with the clinician and the patient, not in statute. HB 324 would create a predictable and dangerous care cliff for patients who have relied on virtual care for months or even years.”

ATA Action testified before the Ohio Senate Health Committee this week and submitted written testimony to Chair Stephen A. Huffman and committee members urging removal of the in-person examination requirement. ATA Action raised the following concerns:

  • Disrupted care for current patients. Thousands of Ohioans currently receive OUD treatment via telehealth. The bill would subject them to retroactive requirements that are clinically unwarranted and logistically impractical.
  • Barriers for rural and underserved Ohioans. Patients would have to travel long distances, arrange childcare, and take time off work for an exam that may not be clinically necessary, which risks delaying treatment and discouraging people from seeking it at all.
  • Ohio would become a national outlier. The bill would make Ohio’s prescribing policy significantly more restrictive than federal standards.
  • Departure from the standard of care. The Federation of State Medical Boards’ model policy holds that care delivered virtually, including prescribing, should meet the same standards of practice as in-person care.

Read the ATA Action opposition letter to the Ohio Senate Health Committee here.

“ATA Action urges Governor DeWine to veto HB 324 and stands ready to work with the governor and Ohio legislators on practical telehealth policy that protects patient access and preserves provider judgment,” Young added.

The evidence supports the effectiveness of telehealth for addiction treatment. A 2023 JAMA Psychiatry study of more than 175,000 Medicare beneficiaries found that receiving OUD-related telehealth services and medications during the COVID-19 pandemic was associated with significantly reduced odds of fatal drug overdose. A 2024 study from Oregon Health & Science University found that patients who initiated buprenorphine in traditional office-based settings had a discontinuation rate more than twice that of patients who initiated via telehealth — 9.7% versus 3.8% over six months.”

About the ATA

The American Telemedicine Association (ATA), the definitive voice for virtual care, is the industry’s trusted community focused on expanding access to healthcare through innovation by advancing education, resources, and policy. Founded in 1993, the ATA represents the most diverse ecosystem in healthcare – including leading health systems, academic medical centers, payers, technology innovators, life sciences companies, and clinician leaders – the ATA delivers clinical standards, policy leadership, education, and evidence frameworks that accelerate high-quality, technology-enabled care.

About ATA Action

ATA Action: Advocacy Shaping Virtual Care expands and protects how virtual care is legislated and regulated at all levels of government. Founded in 2022, ATA Action works collaboratively with federal and state legislators and policymakers to influence legislative and regulatory developments in virtual care, digital health, remote patient monitoring, AI in healthcare, health data privacy, private sector healthcare investment, and more. ATA Action represents hospital systems, technology companies, professional associations, direct-to-consumer digital health providers, payers, pharmaceutical manufacturers, digital therapeutics developers, and remote monitoring organizations, and facilitates member-led coalitions focused on initiatives to advance AI in Virtual Care Policy and Cross State Care. ATA Action is a registered 501(c)(6) nonprofit trade organization engaged in lobbying efforts to shape industry-related legislation and serves as an affiliated trade association of the ATA, a 501(c)(3) entity recognized for its leadership in advancing innovation and leading transformation in virtual care.